Top

Clinical Drug Investigation

Published in:

01-06-2005 | Original Research Article

Effect of Once-Daily Alfuzosin on Urinary Symptoms and Flow Rate in Benign Prostatic Hyperplasia

A 24-Hour Home-Uroflowmetry Evaluation

Authors: Dr Cosimo De Nunzio, Giorgio Franco, Costantino Leonardo, Alberto Trucchi, Andrea Tubaro, Cesare Laurenti

Published in: Clinical Drug Investigation | Issue 6/2005

Abstract

Objective: To analyse the clinical and 24-hour urinary flow efficacy of alfuzosin 10mg once daily (OD), by means of the International Prostate Symptom Score (I-PSS) and home-based uroflowmetry (P-Flow) measurement, in patients with lower urinary tract symptoms (LUTS) related to benign prostatic hyperplasia.

Materials and methods: In this open-label trial, 12 male patients (median age 67 years) with an I-PSS >15 (median 16) and maximum urinary flow (Q_max) <15 mL/sec were evaluated. Patients underwent two days of P-Flow evaluation, and then received alfuzosin 10mg OD from day 3 to day 9. On days 7 and 8 they underwent further P-Flow evaluation. A second post-baseline evaluation I-PSS was recorded on day 9.

Results: Overall, 328 urinary flows were recorded and evaluated, an average of 27 flows per patient. A statistically significant improvement in mean maximum flow: (Q_max) [10.8 ± 2.8 vs 12.4 ± 3 mL/sec; p = 0.02] and urinary voiding volume (219 ± 70 vs 233 ± 55mL; p = 0.04) were observed after treatment compared with baseline. No differences in the number of urinary flows were observed between baseline and after treatment (13 ± 2.9 vs 14 ± 1.8 flows; p = 0.199). A statistically significant difference between the two evaluations was noted for I-PSS (15.7 ± 0.8 and 9.5 ± 2; p = 0.02). Mean Q_max recorded during treatment was always higher than baseline at different daytime evaluations.

Conclusion: The alfuzosin 10mg OD formulation showed a significant improvement in I-PSS as well as a significant improvement in urinary flow parameters (Q_max and urinary voiding volume) lasting for 24 hours in patients with LUTS.

The use of trade names is for product identification purposes only and does not imply endorsement.

Oesterling JE. Benign prostatic hyperplasia: a review of its histogenesis and natural history. Prostate Suppl 1996; 6: 67–73PubMedCrossRef

Skolarikos A, Thorpe AC, Neal DE. Lower urinary tract symptoms and benign prostatic hyperplasia. Minerva Urol Nefrol 2004 Jun; 56(2): 109–22PubMed

Weiner DM, Lowe FC. Alfuzosin for the management of benign prostate hyperplasia. Expert Opin Pharmacother 2003; (4) 11: 2057–63PubMedCrossRef

Andersson KE, Chapple C, El Hilali M, et al. α1-Adrenoceptor antagonists in the treatment of BPH. In: Chatelain C, Denis L, Foo KT, et al., editors. Benign prostatic hyperplasia. Paris: Health Publication Ltd, 2001: 461–77

Lepor M, Williford WO, Barry MJ, et al. The impact of medical therapy on bother due to symptoms, quality of life and global outcome on factors predicting response. Veterans Affairs Cooperative Studies: benign prostatic hyperplasia study group. J Urol 1998; 164(4): 1358–67

McConnell JD, Roehrborn CG, Bautista OM, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003 Dec 18; 349(25): 2387–98PubMedCrossRef

Chapple CR. Pharmacological therapy of benign prostatic hyperplasia/lower urinary tract symptoms: an overview for the practising clinician. BJU Int 2004 Sep; 94(5): 738–44PubMedCrossRef

Caine M. The present role of alpha-adrenergic blockers in the treatment of benign prostatic hyperplasia. J Urol 1986; 136: 1–4PubMed

Gormley GJ, Stoner E, Bruskewitz, et al. The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group. N Engl J Med 1992; 327: 1185–91PubMedCrossRef

10.

Kunisawa Y, Kawabe K, Niijime T, et al. A pharmacological study of alpha adrenergic receptor subtypes in smooth muscle of human urinary bladder and prostatic urethra. J Urol 1985; 134: 396–8PubMed

11.

Jardin A, Bensadoun H, Delauche-Cavallier MC, et al. Alfuzosin for the treatment of benign prostatic hypertrophy. Lancet 1991; 337: 1457–61PubMedCrossRef

12.

Teillac P, Delauche-Cavallier MC, Attali P, et al. Urinary flow rates in patients with benign prostatic hypertrophy following treatment with alfuzosin. Br J Urol 1992; 70: 58–64PubMedCrossRef

13.

McKeage K, Plosker G. Alfuzosin: a review of the therapeutic use of the prolonged-release formulation given once daily in the management of benign prostatic hyperplasia. Drugs 2002; 62: 633–53PubMedCrossRef

14.

Roehrborn CG, Kerrebroeck PV, Nordling J. Safety and efficacy of alfuzosin 10mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of the three double blind placebo controlled studies. Br J Urol 2003; 92: 257–61CrossRef

15.

Schwartz BF, Soderdahl DW, Thrasher JB. Home flow rates in evaluation of lower urinary tract symptoms in men. Tech Urol 1998 Mar; 4(1): 15–7PubMed

16.

de la Rosette JJ, Witjes WP, Debruyne FM, et al. Improved reliability of uroflowmetry investigations: results of a portable home based uroflometry study. Br J Urol 1996; 78: 385–90CrossRef

17.

Boci R, Fall M, Walden M, et al. Home uroflowmetry: improved accuracy in outflow assessment. Neurourol Urodyn 1999; 18(1): 25–32PubMedCrossRef

18.

Scarpa RM. Lower urinary tract symptoms: what are the implications for the patients? Eur Urol 2001; 40Suppl. 4: 12–20PubMedCrossRef

19.

AUA practice guidelines committee. AUA guidelines on management of benign prostatic hyperplasia (2003). Chapter 1: diagnosis and treatment recommendations. J Urol 2003; 170: 530–47CrossRef

20.

Teillac P, Delauche-Cavallier MC, Attali P, et al. Urinary flow rates in patients with benign prostatic hypertrophy following treatment with alfuzosin. Br J Urol 1992; 70: 58–64PubMedCrossRef

21.

Buzeln JM, Roth S, Geffriaud-Ricouard C, et al. Efficacy and safety of sustained-release alfuzosin 5mg in patients with benign prostatic hyperplasia. Eur Urol 1997; 21: 190–8

22.

De Nunzio C, Franco G, Iori F, et al. Clinical and pressure-flow changes after long-term treatment with alfuzosin SR. Urol Int 2003; 71(1): 31–6PubMedCrossRef

23.

van Kerrebroeck P, Jardin A, Laval KU, et al. Efficacy and safety of a new prolonged release formulation of alfuzosin 10mg once daily versus alfuzosin 2.5mg thrice daily and placebo in patients with symptomatic benign prostatic hyperplasia. Eur Urol 2000; 37: 306–13PubMedCrossRef

24.

Djavan B, Marberger M. A meta-analysis on the efficacy and tolerability of α1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol 1999; 36: 1–13PubMedCrossRef

25.

Dicuio M, Creti S, Di Campli A, et al. Usefulness of a prevoiding transabdominal sonographic bladder scan for uroflowmetry in patients involved in clinical studies of benign prostatic hyperplasia. J Ultrasound Med 2003; 22(8): 773–6PubMed

26.

Marks LS, Roehrborn CG, Gittelman M, et al. First dose efficacy of alfuzosin once daily in men with symptomatic benign prostatic hyperplasia. Urology 2003; 62: 888–93PubMedCrossRef

27.

Athoy P, Chretien P, Dupain T, et al. Alfuzosin, an α1-adrenoceptor antagonist for the treatment of benign prostatic hyperplasia: once daily versus three time daily dosing in healthy subjects. Int J Clin Pharmacol Ther 2002; 40: 289–94

28.

van Kerrebroeck P. The efficacy and safety of a new once-a-day formulation of an alpha-blocker. Eur Urol 2001; 39Suppl. 6: 19–26PubMedCrossRef

29.

Abrams P, Griffiths D, Hofner K, et al. The urodynamic assessment of lower urinary tract symptoms. In: Chatelain C, Denis L, Foo KT, et al., editors. Benign prostatic hyperplasia. Paris: Health Publication Ltd, 2001: 227–81

Title: Effect of Once-Daily Alfuzosin on Urinary Symptoms and Flow Rate in Benign Prostatic Hyperplasia
A 24-Hour Home-Uroflowmetry Evaluation
Authors: Dr Cosimo De Nunzio
Giorgio Franco
Costantino Leonardo
Alberto Trucchi
Andrea Tubaro
Cesare Laurenti
Publication date: 01-06-2005
Publisher: Springer International Publishing
Published in: Clinical Drug Investigation / Issue 6/2005
Print ISSN: 1173-2563
Electronic ISSN: 1179-1918
DOI: https://doi.org/10.2165/00044011-200525060-00001

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Effect of Once-Daily Alfuzosin on Urinary Symptoms and Flow Rate in Benign Prostatic Hyperplasia

A 24-Hour Home-Uroflowmetry Evaluation

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2005

Nimesulide-Induced Hepatotoxicity in a Previously Healthy Woman

A Randomised Comparison of the Effects of Nebivolol and Atenolol with and without Chlorthalidone on the Sexual Function of Hypertensive Men

High-Dose N-Acetylcysteine in Patients with Exacerbations of Chronic Obstructive Pulmonary Disease

Successful Treatment with Colesevelam HCl and Pravastatin in a Patient Previously Hospitalised with Severe Normal CPK Myopathy on Introduction of Simvastatin

Bioavailability and Bioequivalence of Two Enteric-Coated Formulations of Omeprazole in Fasting and Fed Conditions

Effect of Imidapril and Nifedipine on Left Ventricular Hypertrophy in Untreated Hypertension